GHK-Cu vs KLOW Blend
GHK-Cu (Copper-binding tripeptide) and KLOW Blend (Multi-component research blend) are documented as co-studied in the PeptiDex library. This page puts the two entries side by side on class, molecular weight, half-life, origin, mechanism and studied research areas — every value taken from the entry it belongs to.
Why these two are co-studied
Cross-referenced for research context — not a usage or combination recommendation.
At a glance
| Attribute | GHK-Cu | KLOW Blend |
|---|---|---|
| Compound class | Copper-binding tripeptide | Multi-component research blend |
| Research category | Cosmetic & Dermal | Healing & Recovery |
| Length (amino acids) | 3 amino acids | Not documented |
| Molecular weight | 340.4 Da | Not documented |
| Half-life | Not documented | Not documented |
| Origin | GHK is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, with levels reported to decline with age. GHK-Cu is its complex with copper(II) ions and is widely used as a cosmetic ingredient. | KLOW is a marketed multi-component research blend. It is typically described as combining GHK-Cu (copper tripeptide), KPV (an alpha-MSH fragment), and a BPC-157 / TB-500 combination. Exact composition can vary by supplier and it is not a naturally occurring substance. |
“Not documented” means the PeptiDex entry records no value for that field. Nothing on this page is estimated, and no figure is carried over from one compound to the other.
How GHK-Cu works
GHK has a high affinity for copper(II) and is understood to act partly as a copper-delivery molecule, facilitating copper transport relevant to enzymatic and remodeling processes. In cell and skin research it has been associated with signaling that influences extracellular-matrix remodeling, collagen and glycosaminoglycan synthesis, and antioxidant and gene-expression effects. Much of this work is from in-vitro and skin studies.
How KLOW Blend works
As a blend, KLOW combines the documented properties of its components: GHK-Cu's copper-delivery and tissue-remodeling signaling, KPV's melanocortin-pathway anti-inflammatory activity, BPC-157's angiogenesis and growth-factor-related repair signaling, and TB-500's actin-regulation and cell-migration effects. These properties come from separate preclinical and cosmetic research; the combined formulation is not independently validated in controlled human trials.
Mechanistic descriptions reflect published research-literature understanding and are quoted from each compound's own entry. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.
Where each one appears in the literature
The research contexts each entry documents. Listing a research area is not a claim of efficacy or a therapeutic indication, and the two lists are not scored against each other.
GHK-Cu
KLOW Blend
What sets each apart
GHK-Cu
GHK-Cu is the most established copper tripeptide in cosmetic use, distinguished from AHK-Cu by its sequence and from repair peptides like BPC-157 by its remodeling and copper-delivery focus.
KLOW Blend
KLOW is a broader combination than two-component blends, pairing a copper cosmetic tripeptide and an anti-inflammatory MSH fragment with repair-focused peptides.
Documented together as a research blend
Cross-referenced for research context — not a usage or combination recommendation.
Frequently asked questions
What is GHK-Cu?
GHK-Cu is a complex of the naturally occurring tripeptide GHK (glycyl-L-histidyl-L-lysine) with a copper(II) ion. The GHK sequence is a subfragment of the alpha-2 chain of type I collagen and is present in human plasma, where its level declines with age. It is studied primarily as a copper-delivery and skin-remodeling signal peptide.
What is GHK-Cu studied for?
In research and cosmetic-formulation literature it is studied for collagen and glycosaminoglycan synthesis in dermal fibroblasts, wound-model remodeling, and antioxidant/gene-modulating activity. It is characterized as a signaling peptide rather than a therapeutic drug, and is not FDA-approved for treating any condition.
Why is a higher GHK-Cu concentration not necessarily better?
Research summaries note a biphasic dose response: GHK-Cu stimulates matrix synthesis at low (picomolar to nanomolar) concentrations, but at higher concentrations it can also upregulate matrix-degrading enzymes. This is why most cosmetic formulation guidance centers on the low end of the topical range rather than maximizing concentration.
What is the KLOW blend and what does the name mean?
KLOW is a four-component research blend most commonly composed of KPV, GHK-Cu, BPC-157, and TB-500. The name is generally described as KPV added to the GLOW blend, where GLOW is GHK-Cu + BPC-157 + TB-500. Exact composition and ratios vary by supplier, so the vial's COA is the authoritative source.
What is each component in KLOW contributing?
In research terms, GHK-Cu (copper tripeptide) is studied for gene-expression modulation and tissue remodeling, BPC-157 for angiogenic and nitric-oxide signaling, TB-500 for actin dynamics and cell migration, and KPV for anti-inflammatory NF-kB modulation. The blend is used to study combined tissue-repair and inflammation pathways rather than any single target. All such effects are preclinical.
What is a typical KLOW vial composition?
One commonly cited configuration is an 80 mg vial containing roughly 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV. Other vendors use different totals and ratios, so this should be verified against the specific product's certificate of analysis rather than assumed.
Answers are the ones published on each compound's own PeptiDex entry. They are educational summaries of research-literature context and are not medical advice.